How Value Analysis Committees’ Lines of Questioning Can Directly Affect Value Equation Outputs

By AHRMM

John Kelty from W.L. Gore & Associates discusses how value analysis committees can determine a medical devices value when evaluating new products. 

Related Resources

Advisory
Statement on Pricing Transparency
AHRMM’s Issues & Legislative Committee issued the following Statement on Pricing Transparency approved by AHRMM Board of Directors:<
Guides/Reports
Crossing the Quality Chasm: A New Health System for the 21st Century
Supply Chain Strategies & Solutions Article
The Future for Effective Healthcare Supply Change Is Balancing Cost, Quality, and Outcomes
Supply chain must play an integral role in the care delivery process through cross-departmental partnerships that support evidence-based valu
White Papers
The Impact of Reform and the Recession on Supply Chain Management
A recap of the Executive Thought Leader Forum hosted by AHRMM on August 6, 2012, to discuss the transforming healthcare environment.
Guides/Reports
Report Demonstrates Hospitals Value Group Purchasing Organizations
 
Letter/Comment
The Official Comment of AHRMM to the United States Department of Health and Human Services Food and Drug Administration (FDA) regarding Unique Device Identification for Medical Devices Docket No. FDA-2011-N-0090
AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Fo